comprehensive -WSS

comprehensive

author：fashion 2025-10-02 02:37:53 - browse：325

Adobe

Akili Interactive, which in 2020 made waves by receiving Food and Drug Administration clearance for its video game that improves symptoms of ADHD in children, on Wednesday announced it would reorient its business around selling its products directly to users over the counter, rather than by prescription.

In connection with the move away from prescription sales, Akili will reduce its workforce by 40%, which the company projects will extend its runway into the second half of 2025. The Boston-based company will continue offering its pediatric treatment, EndeavorRx, by prescription until it can convert it to over-the-counter labeling — it plans to submit data to FDA in 2024.

Akili went public last year and though its prescription sales were slowly increasing, the company’s costs far outstripped its revenues. In its second-quarter results reported in August, Akili said it earned just $114,000 on $15.3 million in expenses.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Wikipedia

WSS

Kenai launches with $82 million for Parkinson’s stem cell therapy

Congressmen charge Covid hearing ‘could have been an email’

General Catalyst, Summa Health deal will turn on physician buy

A $475,000 price tag for a new cancer drug: crazy or meh?

General Catalyst, Summa Health deal will turn on physician buy

Biden administration opens offers in Medicare drug price negotiations

entertainment

comprehensive

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Scientists unlock the key to scar

Malaria cases in Florida and Texas: Here’s what you need to know

Quicker fix for pulse oximeters urged during FDA public meeting

Malaria cases in Florida and Texas: Here’s what you need to know

Vertex non

Apple is now the first public company to be valued at $3 trillion

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

The high cost of giving birth even with insurance

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

hotspot

AstraZeneca loses challenge to Medicare drug price negotiation

New Ultima Genomics DNA sequencer can read genome for $100

How to fix the rural physician shortage in the U.S.

House looks to weaken Medicare negotiation

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

An inside look at PIPEs, biotech's buzzy new financing tool

Wikipedia

hotspot

hotspot

knowledge